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Yacute myocardial infarction. In addition subjects with B2/C lesions, which are
known to have a higher risk for cardiac complications or restenosis have been
evaluated.
RESULTS Nine hundred seventy one men (72%) and three hundred eighty ﬁve
women were enrolled at 43 sites in 14 countries. The mean age was 66.1  10.7,
ranging from 29 - 91 years. The majority of subjects presented with hypertension 76%,
hypercholesteremia 60%, smoker 55%, and diabetes 30%. 48% of all stented vessels
had a diameter 2.75mm, 4% presented with chronic total occlusion. Eleven percent
of the subjects experienced unstable angina, 47% stable angina. Acute MI was seen in
33% of the subjects (NSTEMI 22%, STEMI 11%). The portion of elderly subjects (75
years) is represented by 25%. An unbiased patient population was seen in the registry
with more than 52% type B2/C lesions. Moderate and severe calciﬁcation was
observed in 31%. The Orsiro hybrid stent system demonstrated excellent device
(98.7%) and procedure success (98.2%). In this all-comers setting a TLF rate of 5.1%
was observed within the ﬁrst 12 months. The low TLF rate was also conﬁrmed for the
subgroups: diabetics (7.7%), acute MI (7.2%), small vessel (5.8%), CTO (1.8%) and
complex B2/C lesions (5.1%).
CONCLUSION The results observed in this “real world” population demonstrate a low
TLF rate comparable to other state of the art DES at 6- and 12-months.
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OBJECTIVES BIOFLOW-II is a randomized controlled study, comparing the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience Prime) at 2 Years in the complete study population
as well as in the diabetic and small vessel subgroups, which are known to have a
higher risk for cardiac complications. Here we present the outcome through the
clinical endpoints Target Lesion Failure (TLF) and Stent Thrombosis (ST).
METHODS A total of N¼452 subjects (62.710.4, 38-80 yrs) were enrolled in the
Intention to Treat population in the BIOFLOW-II study, registered at clinicaltrials.
gov (NCT01356888). All subjects were stratiﬁed for diabetes and then randomly
assigned (2:1) to receive the Orsiro or the Xience Prime stent. The diabetic subgroup
accounted for 28.3% N¼128 (Orsiro N¼84, Xience Prime N¼44) of all subjects. The
small vessel cohort included all subjects with a reference vessel diameter 2.75mm,
accounting for 57.3% N¼259 (Orsiro N¼168, Xience Prime N¼91) of all subjects.
Clinical follow up visits are performed at 1, 6, 12 months and annually up to 5 years
after the procedure. All angiographic images were analyzed by an independent
Corelab. All clinical events were adjudicated by an independent clinical events
committee.
RESULTS All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The TLF rate at 24 months was 8.4% for the Orsiro vs. 10.0% for
the Xience Prime in the full cohort, 9.7%vs. 9.1% in the diabetic subgroup and 9.4%
vs. 13.3% for subjects with small vessel lesions. There was no statistical signiﬁcance
between the two study arms in any of the three analyzed populations. No ST
(deﬁnitive, probable or possible) occurred through 24 months in the Orsiro arm.
Conclusion In this RCT the clinical event rates of the Orsiro SES with a biodegradable
polymer were low and comparable to the Xience Prime up to 24 month in all three
analyzed populations.
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BACKGROUND The aim of this study is to investigate whether age increase affects the
decision to use drug-eluting stents (DES) in elderly patients undergoing percutaneous
coronary intervention (PCI).METHODS This is a single center registry including elderly patients ( 65 year-old)
undergoing PCI. We deﬁned ﬁrst DES era as the period between April 2003 and July
2008, and second DES era the period of July 2008 to March 2014. Multivariable model
was created for both eras to assess the independent factors associated with DES im-
plantation and the impact of age (per 10 year increase).
RESULTS A total of 8,598 elderly patients were included, of whom 4,528 (52.7%) and
4,070 (47.3%) underwent PCI in the ﬁrst and second generation DES eras, respec-
tively. Multivariable logistic regression showed that age increase of per 10 years was
associated with less likelihood to receive DES implantation. Similarly, patients with
acute myocardial infarction, chronic renal insufﬁciency, chronic heart failure, cardiac
shock and current smoking were less likely to receive DES in the two DES eras.
CONCLUSION Among elderly patients undergoing PCI, age is independently associ-
ated with a lower likelihood of DES implantation in the second generation era. This
ﬁnding may highlight the clinical difﬁculty in assessing the risk/beneﬁt balance of
DES in the elderly population.
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BACKGROUND We previously reported that the incidence of 1-year major adverse
cardiac events (MACE) in patients treated with paclitaxel-eluting stents (PES) was
lower than that in the sirolimus-eluting stents, mainly due to reduction of target
lesion revascularization (TLR) in dialysis patients. However, it is unclear whether
there are differences in clinical outcomes between everolimus-eluting stents (EES)
and PES in dialysis patients.
METHODS Between February 2010 and September 2013, 248 maintenance dialysis
patients were treated with coronary stents. In this study, 102 maintenance dialysis
patients with 135 lesions treated with EES were compared to 107 maintenance
dialysis patients with 147 lesions treated with PES. Of these, 60 patients were pro-
spectively randomized to either EES (32 patients) or PES (28 patients) between March
2011 and September 2013. Angiographic and 1-year clinical outcomes were
investigated.
RESULTS Diabetes mellitus (DM) was present in 64.7% in the EES group and 71.0% in
the PES group (p¼0.33). Dialysis period was 6.4  6.3 years vs 6.2  5.9 years
respectively (p¼0.77). Heavy calciﬁcation was in 27.4% vs 34.0% (p¼0.23). In-stent
restenosis lesion was in 14.1% vs 10.9% (p¼0.42). There were no signiﬁcant differ-
ences in reference diameter (2.62  0.64mm vs 2.66  0.60mm, p¼0.52) and lesion
length (15.0  12.2mm vs 16.5  11.4mm, p¼0.29). Rotational atherectomy was un-
dergone in 11.1% vs 23.1% (p<0.01). Total stented length was not signiﬁcantly
different (23.5  14.6mm vs 24.4  13.2mm, p¼0.60). One patient in the EES group
was lost to follow up. Angiographic follow-up was obtained in 73.3% vs 74.8%
(p¼0.77). Restenosis rate was not signiﬁcantly different (18.2% vs 13.6%, p¼0.37). At
12 months, MACE occurred in 13.2% in the EES group and 17.4% in the PES group
(p¼0.25). TLR was observed in 9.5% vs 10.4% respectively (p¼0.77). Mortality was
11.8% vs 13.1% (p¼0.35). Cardiac death was 5.0% vs 7.7% (p¼0.09). Deﬁnite stent
thrombosis was observed in 2.0% vs 0% (p¼0.14). Subgroup analysis in patients with
DM revealed no signiﬁcant differences in MACE (12.7% vs 14.9%, p¼0.36), TLR (8.3%
